Pharmacogenomics research and development innovator PharmaGenoma, Inc. and its subsidiary HairDX, LLC announced an exclusive agreement with Aderans Company Limited of Tokyo to introduce the tests in Japan starting on March 1, 2009. The HairDX test collection kit is listed with Japan's Pharmaceuticals and Medical Devices Agency (PMDA) as a Class I medical device. The agreement makes Aderans the sole Japanese distributor of HairDX’s revolutionary genetic tests, and further expands Aderans’ leadership in the hair care and medical fields. “PharmaGenoma is a leader in molecular dermatology and is excited to bring the latest in genetic science to Japan. We believe our partnership with Aderans will benefit millions of Japanese men and women concerned about hair loss,” says Andy Goren, President & CEO of PharmaGenoma, Inc. HairDX’s simple genetic test provides an accurate and understandable genetic analysis of a man’s or woman’s likelihood of developing Androgenetic Alopecia, the most common type of hair loss. ”Aderans partnership with HairDX will allow people in Japan to learn their risk for hair loss early, so they can choose the best treatment to preserve their hair,” says Katsuji Tokumaru, President of Aderans Co. Ltd.